

Measles and rubella elimination country profile

Cyprus

Measles elimination status

2015 eliminated
2016 eliminated




Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

National plan of action

Does the country have a national plan of action?
Action plan is being finalized

Is it updated? Yes



Source: Rubella Elimination Annual Status Update report, 2016
NA= Not applicable


Measles and rubella immunization schedule, 2016

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	12-15 Months	MCV2	1989
MCV2	MMR	4-6 years	RCV	1974
Measles vaccination in school				Yes

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)
MMR = measles-mumps-rubella-containing vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Definition used for an outbreak

Cases of measles or rubella more than the expected for a specific area and time




Source: Measles and rubella elimination Annual Status Update report, 2016



Rubella elimination status

2015 eliminated
2016 eliminated




Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

Demographic information, 2016

Total population	1 176 598
< 1 year old	13 002
< 5 years old	65 439


Source: World Population Prospects: The 2015 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2007-2016



Source: Disease incidence and immunization coverage, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)
MCV1 = first dose of measles-containing vaccine
MCV2 = second dose of measles-containing vaccine

Confirmed measles cases by month of onset, 2012-2016



Source: CISID2 2016

Measles and rubella elimination country profile Cyprus

Measles incidence, epidemiologic and virologic characteristics, 2012-2016

	Suspected measles cases	Confirmed measles cases				Discarded as non-measles	Measles incidence	Genotypes detected
		Laboratory	Epi- linked	Clinically	Total			
2012	0	0	0	0	0	0	0	NA
2013	0	0	0	0	0	0	0	NA
2014	153	8	2	0	8	145	11.6	ND
2015	204	0	0	0	0	204	0	NA
2016	17	0	0	0	0	17	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2012-2016

	Discarded non-measles rate	% 1st sub-national unit with > 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2012	ND	ND	ND	ND	ND	ND	ND	ND
2013	ND	ND	ND	ND	ND	ND	ND	ND
2014	16.9	100%	98.7%	100%	153	5.2%	0	ND
2015	24.1	ND	100%	NA	204	0%	NA	100%
2016	2	100%	100%	NA	17	0%	NA	100%

Source: ASU 2012-2016, MeaNS 2012-2016 and laboratory accreditation results 2012-2016
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella incidence, epidemiologic and virologic characteristics, 2012-2016

	Suspected rubella cases	Confirmed measles cases				Discarded as non-rubella	Rubella incidence	Genotypes detected
		Laboratory	Epi- linked	Clinically	Total			
2012	0	0	0	0	0	0	0	NA
2013	0	0	0	0	0	0	0	NA
2014	144	0	0	0	0	144	0	NA
2015	386	0	0	0	0	386	0	NA
2016	0	0	0	0	0	0	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Rubella surveillance and laboratory performance indicators, 2012-2016

	Discarded non-rubella rate	% 1st sub-national unit with > 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2012	ND	ND	ND	ND	ND	ND	ND	ND
2013	ND	ND	ND	ND	ND	ND	ND	ND
2014	16.7	100%	100%	NA	144	0%	NA	ND
2015	45.6	100%	100%	NA	386	0%	NA	100%
2016	8.4	100%	100%	NA	71	0%	NA	100%

Source: ASU 2012-2016, RubeNS 2012-2016 and laboratory accreditation results 2012-2016
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2016 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Cyprus in 2016, and confirmed that measles and rubella elimination has been sustained. The RVC commends the programmatic initiatives including development of the measles and rubella action plan and introduction of the personal immunization record system. The RVC acknowledges the increase in MRCV2 coverage in 2016 and commends the activities undertaken to provide immunization to the migrants and refugee population. RVC urges the national health authorities to consider additional activities to improve the MRCV coverage in the country.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: \geq 80%
- % origin of infection known: \geq 80%
- Rate of viral detection: \geq 80%

Information on CRS, 2016

No cases reported

Source: Measles and rubella elimination Annual Status Update report, 2016
CRS = congenital rubella syndrome